Brief: Medicenna Therapeutics Presents Clinical Validation Of IL4 Receptor As A Biomarker For MDNA55 In Recurrent Glioblastoma
03/06/2019 12:55
June 3 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA PRESENTS CLINICAL VALIDATION OF THE IL4 RECEPTOR
AS A
BIOMARKER FOR MDNA55 IN RECURRENT GLIOBLASTOMA
* MEDICENNA THERAPEUTICS CORP - 75% OF IL4R(+VE) PATIENTS
ACHIEVE
DISEASE CONTROL FOLLOWING ONE TREATMENT WITH MDNA55
* MEDICENNA THERAPEUTICS CORP - ENROLMENT INTO PHASE 2B
MDNA55-05
TRIAL HAS BEEN COMPLETED.
Source text for Eikon: ID:nPn4DRBgca
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results